137 related articles for article (PubMed ID: 34302862)
1. Phenotypic characterization of cell culture-derived hepatitis E virus subjected to different chemical treatments: Application in virus removal via nanofiltration.
Ideno S; Inoue T; Takahashi K; Urayama T; Maeno H; Takeuchi K; Sakai K
J Virol Methods; 2021 Oct; 296():114244. PubMed ID: 34302862
[TBL] [Abstract][Full Text] [Related]
2. Antibody-enhanced hepatitis E virus nanofiltration during the manufacture of human immunoglobulin.
Kapsch AM; Farcet MR; Wieser A; Ahmad MQ; Miyabayashi T; Baylis SA; Blümel J; Kreil TR
Transfusion; 2020 Nov; 60(11):2500-2507. PubMed ID: 32794187
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis E virus and the safety of plasma products: investigations into the reduction capacity of manufacturing processes.
Farcet MR; Lackner C; Antoine G; Rabel PO; Wieser A; Flicker A; Unger U; Modrof J; Kreil TR
Transfusion; 2016 Feb; 56(2):383-91. PubMed ID: 26399175
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the Quasi-Enveloped Hepatitis E Virus Particles Released by the Cellular Exosomal Pathway.
Nagashima S; Takahashi M; Kobayashi T; ; Nishizawa T; Nishiyama T; Primadharsini PP; Okamoto H
J Virol; 2017 Nov; 91(22):. PubMed ID: 28878075
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis E virus derived from different sources exhibits different behaviour in virus inactivation and/or removal studies with plasma derivatives.
Yunoki M; Tanaka H; Takahashi K; Urayama T; Hattori S; Ideno S; Furuki R; Sakai K; Hagiwara K; Ikuta K
Biologicals; 2016 Sep; 44(5):403-11. PubMed ID: 27461242
[TBL] [Abstract][Full Text] [Related]
6. Extent of hepatitis E virus elimination is affected by stabilizers present in plasma products and pore size of nanofilters.
Yunoki M; Yamamoto S; Tanaka H; Nishigaki H; Tanaka Y; Nishida A; Adan-Kubo J; Tsujikawa M; Hattori S; Urayama T; Yoshikawa M; Yamamoto I; Hagiwara K; Ikuta K
Vox Sang; 2008 Aug; 95(2):94-100. PubMed ID: 18714441
[TBL] [Abstract][Full Text] [Related]
7. Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E.
Soon CF; Behrendt P; Todt D; Manns MP; Wedemeyer H; Sällberg Chen M; Cornberg M
J Hepatol; 2019 Oct; 71(4):673-684. PubMed ID: 31203151
[TBL] [Abstract][Full Text] [Related]
8. Rescue of a genotype 4 human hepatitis E virus from cloned cDNA and characterization of intergenotypic chimeric viruses in cultured human liver cells and in pigs.
Córdoba L; Feagins AR; Opriessnig T; Cossaboom CM; Dryman BA; Huang YW; Meng XJ
J Gen Virol; 2012 Oct; 93(Pt 10):2183-2194. PubMed ID: 22837416
[TBL] [Abstract][Full Text] [Related]
9. Risk for Hepatitis E Virus Transmission by Solvent/Detergent-Treated Plasma.
Gallian P; Lhomme S; Morel P; Gross S; Mantovani C; Hauser L; Tinard X; Pouchol E; Djoudi R; Assal A; Abravanel F; Izopet J; Tiberghien P
Emerg Infect Dis; 2020 Dec; 26(12):2881-2886. PubMed ID: 33219652
[TBL] [Abstract][Full Text] [Related]
10. Efficient cell culture systems for hepatitis E virus strains in feces and circulating blood.
Okamoto H
Rev Med Virol; 2011 Jan; 21(1):18-31. PubMed ID: 21294213
[TBL] [Abstract][Full Text] [Related]
11. Isolation of Subtype 3c, 3e and 3f-Like Hepatitis E Virus Strains Stably Replicating to High Viral Loads in an Optimized Cell Culture System.
Schemmerer M; Johne R; Erl M; Jilg W; Wenzel JJ
Viruses; 2019 May; 11(6):. PubMed ID: 31141895
[TBL] [Abstract][Full Text] [Related]
12. Generation of a Bactrian camel hepatitis E virus by a reverse genetics system.
Zhang W; Ami Y; Suzaki Y; Doan YH; Takeda N; Muramatsu M; Li TC
J Gen Virol; 2021 Jul; 102(7):. PubMed ID: 34242156
[TBL] [Abstract][Full Text] [Related]
13. Persistent infection with a rabbit hepatitis E virus created by a reverse genetics system.
Zhang W; Ami Y; Suzaki Y; Doan YH; Jirintai S; Takahashi M; Okamoto H; Takeda N; Muramatsu M; Li TC
Transbound Emerg Dis; 2021 Mar; 68(2):615-625. PubMed ID: 32649803
[TBL] [Abstract][Full Text] [Related]
14. Nanofiltration of plasma-derived biopharmaceutical products.
Burnouf T; Radosevich M
Haemophilia; 2003 Jan; 9(1):24-37. PubMed ID: 12558776
[TBL] [Abstract][Full Text] [Related]
15. Characterization and epitope mapping of monoclonal antibodies raised against rat hepatitis E virus capsid protein: An evaluation of their neutralizing activity in a cell culture system.
Kobayashi T; Takahashi M; Tanggis ; Mulyanto ; Jirintai S; Nagashima S; Nishizawa T; Okamoto H
J Virol Methods; 2016 Jul; 233():78-88. PubMed ID: 26992654
[TBL] [Abstract][Full Text] [Related]
16. Culture systems for hepatitis E virus.
Okamoto H
J Gastroenterol; 2013 Feb; 48(2):147-58. PubMed ID: 23104469
[TBL] [Abstract][Full Text] [Related]
17. Development and evaluation of an efficient cell-culture system for Hepatitis E virus.
Tanaka T; Takahashi M; Kusano E; Okamoto H
J Gen Virol; 2007 Mar; 88(Pt 3):903-911. PubMed ID: 17325363
[TBL] [Abstract][Full Text] [Related]
18. Nanofiltration as a robust method contributing to viral safety of plasma-derived therapeutics: 20 years' experience of the plasma protein manufacturers.
Roth NJ; Dichtelmüller HO; Fabbrizzi F; Flechsig E; Gröner A; Gustafson M; Jorquera JI; Kreil TR; Misztela D; Moretti E; Moscardini M; Poelsler G; More J; Roberts P; Wieser A; Gajardo R
Transfusion; 2020 Nov; 60(11):2661-2674. PubMed ID: 32815181
[TBL] [Abstract][Full Text] [Related]
19. Rat hepatitis E virus derived from wild rats (Rattus rattus) propagates efficiently in human hepatoma cell lines.
Jirintai S; Tanggis ; Mulyanto ; Suparyatmo JB; Takahashi M; Kobayashi T; Nagashima S; Nishizawa T; Okamoto H
Virus Res; 2014 Jun; 185():92-102. PubMed ID: 24631787
[TBL] [Abstract][Full Text] [Related]
20. Serological and molecular evidence of a plausible transmission of hepatitis E virus through pooled plasma.
Andonov A; Rock G; Lin L; Borlang J; Hooper J; Grudeski E; Wu J;
Vox Sang; 2014 Oct; 107(3):213-9. PubMed ID: 24830322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
